

EKterly[®]
(sebetralstat) tablets 300 mg

No matter where a hereditary angioedema
(HAE) attack occurs, you can

TREAT IT STOP IT

F A S T



CARI, real EKTERLY patient

EKTERLY is the first and only oral on-demand treatment that provides rapid relief from HAE attacks, with a median time of 1.8 hours to beginning of symptom relief.*

*Analysis does not include attacks where response information was not provided. In product label, these attacks were included as having no response to treatment at 12 hours, shifting median to 2.0 hours.

WHAT IS EKTERLY[®] (sebetralstat)?

EKTERLY is a prescription medicine used to treat sudden (acute) attacks of hereditary angioedema (HAE) in adults and children aged 12 years of age and older. It is not known if EKTERLY is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION

Before taking EKTERLY, tell your healthcare provider about all of your medical conditions, including if you:

- **Are pregnant or planning to become pregnant. It is not known if EKTERLY can harm your unborn baby.**

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

Say hello to

Ekterly®

“There are so many things I have confidence doing now because I know I can treat my attacks on-demand with EKTERLY.”

–CARI, real EKTERLY patient

An oral acute treatment that can go wherever you do



Effective against all types of attacks whether you're on preventative therapy or not.



Proven to begin providing symptom relief fast.



Safety events were similar to placebo.

IMPORTANT SAFETY INFORMATION (continued)

Before taking EKTERLY, tell your healthcare provider about all of your medical conditions, including if you:

- Are breastfeeding or plan to breastfeed. It is not known if EKTERLY passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking EKTERLY.
- Have liver problems.

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

Ekterly®
(sebetralstat) tablets 300 mg

EKTERLY provides a fast start to symptom relief

EKTERLY was studied in the largest on-demand clinical trial of 97 adults and 13 children (12 years of age and older) with either type I or type II HAE.

Median time to the beginning of symptom relief was



*Analysis does not include attacks where response information was not provided. In product label, these attacks were included as having no response to treatment at 12 hours, shifting median to 2.0 hours.

“I’m able to enjoy more outdoor activities with my sons and be more present in the moment.”


–CARI, real EKTERLY patient



Works for any type of attack

The time it took for people to start feeling relief after taking EKTERLY was similar regardless of:

- Age (12 years and older)
- Whether or not they were on preventative treatment
 - 23% of patients were on preventative and 77% treated with on-demand treatment only
- Attack location and severity



96% of attacks that were effectively treated with EKTERLY required just 1 dose.

IMPORTANT SAFETY INFORMATION (continued)

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking EKTERLY with certain other medicines can cause side effects or affect how well EKTERLY or the other medicines work. Especially tell your healthcare provider if you take any of the following, as their use with EKTERLY is not recommended: itraconazole, phenytoin, efavirenz.

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.



The safety of EKTERLY was similar to placebo

Based on the total number of patients who treated 264 attacks:

SIDE EFFECT	EKTERLY 600 mg n=93	PLACEBO n=83
Headache, no. (%)	3 (3.2)	1 (1.2)

- No serious side effects related to EKTERLY were reported
- ZERO people dropped out of the clinical study due to side effects

Visit EKTERLY.com/Results to learn more about the EKTERLY clinical study.



Taking EKTERLY is easy



Take 2 pills* after recognizing an attack.

- Take **with or without food**
- **No preparation**, setup, or refrigeration required



There have been no reports of difficulty swallowing EKTERLY during laryngeal attacks.



EKTERLY is designed to be quickly absorbed higher up in the digestive system than where stomach attacks typically occur.

If needed, you may take another 2 pills at least 3 hours after your first dose. Do not take more than 4 pills in a 24-hour period.

*Unless otherwise directed by your healthcare provider.

IMPORTANT SAFETY INFORMATION (continued)

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.





You're not alone. **KalVista Cares™** is here to help.

Your next dose is already in reach. From enrollment to refill, we're with you every step of the way.

Living with HAE can bring unique challenges, and at KalVista Cares, we understand how important it is to feel supported. That's why our dedicated Care Managers are here to help ensure you have the treatment you need, when you need it.

Upon enrollment, your Care Manager can help you:



Navigate insurance coverage and minimize delays in accessing EKTERLY.



Evaluate your eligibility for financial support programs that may help cover the cost of EKTERLY.



Work with your specialty pharmacy **to help ensure you receive your treatment.**

QuickStart Program



KalVista Cares may help eligible patients with temporary treatment options while awaiting coverage determination.*

*For new patients only.

Explore **financial assistance options**

KalVista Cares Co-Pay Assistance Program



With the KalVista Cares Co-Pay Assistance Program, eligible commercially insured patients may **pay as little as \$0** for their EKTERLY prescription.[†]

[†]Terms and conditions apply. Please visit EKTERLY.com/GettingEKTERLY for more details.

To learn more about **KalVista Cares:**

- Visit EKTERLY.com/GettingEKTERLY
- Call [1-844-432-3322](tel:1-844-432-3322)

Care Managers are available to assist you, **Monday-Friday between 8:30 am-8 pm ET.**



CARI, real EKTERLY patient

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.



Connect through EKTERLY Educational Events



Learn about EKTERLY from a healthcare professional who treats HAE patients



Hear from a patient or caregiver and their experience with EKTERLY



Better understand the KalVista Cares™ patient support program



Get your questions answered during a Q&A session

Find an event near you and **RSVP** today:

Visit
[EKTERLY.com/Events](https://www.ekterly.com/events)



or

Call
1-866-522-2639



or

Text "RSVP" to
85371*



*By texting 85371, you agree to receive text messages from EKTERLY Events about your registration and event updates. To opt out at any time, text STOP. Message and data rates may apply. Message frequency varies.

Considering switching your acute treatment?

Researchers looked back at the clinical study to understand patient satisfaction after switching treatments.

Out of 1,089 attacks treated in the extended trial,

84% of patients said they were **satisfied with EKTERLY as their treatment.**

Talk to your doctor to see if EKTERLY is right for you.
Download our Doctor Discussion Guide.

IMPORTANT SAFETY INFORMATION

Before taking EKTERLY, tell your healthcare provider about all of your medical conditions, including if you:

- **Are pregnant or planning to become pregnant. It is not known if EKTERLY can harm your unborn baby.**
- **Are breastfeeding or plan to breastfeed. It is not known if EKTERLY passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking EKTERLY.**
- **Have liver problems.**

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking EKTERLY with certain other medicines can cause side effects or affect how well EKTERLY or the other medicines work. Especially tell your healthcare provider if you take any of the following, as their use with EKTERLY is not recommended: itraconazole, phenytoin, efavirenz.

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

What are the possible side effects of EKTERLY?

The most common side effects of EKTERLY include headache. For more information, ask your healthcare provider or pharmacist. Talk to your doctor for medical advice about side effects.

You are encouraged to report side effects related to KalVista products by calling **1-855-258-4782.**

If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly.

Visit www.fda.gov/medwatch or call **1-800-FDA-1088**.

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

Ekterly®
(sebetralstat) tablets 300 mg

Ekterly®

(sebetralstat) tablets 300 mg

The acute pill with a fast start of symptom relief



CONVENIENT

A quick and convenient oral treatment.



EFFECTIVE

2 pills for fast start of symptom relief.



EVERY ATTACK

Can treat any type of HAE attack wherever you are.

WHAT IS EKTERLY® (sebetralstat)?

EKTERLY is a prescription medicine used to treat sudden (acute) attacks of hereditary angioedema (HAE) in adults and children aged 12 years of age and older. It is not known if EKTERLY is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION

Before taking EKTERLY, tell your healthcare provider about all of your medical conditions, including if you:

- Are pregnant or planning to become pregnant. It is not known if EKTERLY can harm your unborn baby.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including [Patient Information](#).

CARI, real EKTERLY patient

Talk to your doctor
or learn more at

Ekterly.com



©2026 KalVista Pharmaceuticals, Inc. All rights reserved. KalVista, the KalVista logo, and EKTERLY are registered trademarks of KalVista Pharmaceuticals. US-SEB-00116v2 05/26